Panbela Therapeutics (PBLA) Competitors $0.32 -0.01 (-1.52%) (As of 12/20/2024 05:32 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends PBLA vs. ONVO, SYRS, GTBP, CNSP, HOTH, PPBT, CANF, ELAB, IMCC, and AEZSShould you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include Organovo (ONVO), Syros Pharmaceuticals (SYRS), GT Biopharma (GTBP), CNS Pharmaceuticals (CNSP), Hoth Therapeutics (HOTH), Purple Biotech (PPBT), Can-Fite BioPharma (CANF), Elevai Labs (ELAB), IM Cannabis (IMCC), and Aeterna Zentaris (AEZS). These companies are all part of the "pharmaceutical products" industry. Panbela Therapeutics vs. Organovo Syros Pharmaceuticals GT Biopharma CNS Pharmaceuticals Hoth Therapeutics Purple Biotech Can-Fite BioPharma Elevai Labs IM Cannabis Aeterna Zentaris Organovo (NASDAQ:ONVO) and Panbela Therapeutics (NASDAQ:PBLA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability and media sentiment. Does the media favor ONVO or PBLA? In the previous week, Organovo's average media sentiment score of 0.00 equaled Panbela Therapeutics'average media sentiment score. Company Overall Sentiment Organovo Neutral Panbela Therapeutics Neutral Which has stronger earnings & valuation, ONVO or PBLA? Organovo has higher revenue and earnings than Panbela Therapeutics. Organovo is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganovo$103K53.71-$14.67M-$1.06-0.34Panbela TherapeuticsN/AN/A-$25.26M-$71.130.00 Do analysts recommend ONVO or PBLA? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organovo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Panbela Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility and risk, ONVO or PBLA? Organovo has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Panbela Therapeutics has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Does the MarketBeat Community favor ONVO or PBLA? Organovo received 178 more outperform votes than Panbela Therapeutics when rated by MarketBeat users. However, 62.07% of users gave Panbela Therapeutics an outperform vote while only 47.34% of users gave Organovo an outperform vote. CompanyUnderperformOutperformOrganovoOutperform Votes19647.34% Underperform Votes21852.66% Panbela TherapeuticsOutperform Votes1862.07% Underperform Votes1137.93% Is ONVO or PBLA more profitable? Panbela Therapeutics has a net margin of 0.00% compared to Organovo's net margin of -12,176.70%. Panbela Therapeutics' return on equity of 0.00% beat Organovo's return on equity.Company Net Margins Return on Equity Return on Assets Organovo-12,176.70% -249.28% -159.50% Panbela Therapeutics N/A N/A -302.61% Do insiders and institutionals have more ownership in ONVO or PBLA? 8.2% of Organovo shares are held by institutional investors. Comparatively, 4.4% of Panbela Therapeutics shares are held by institutional investors. 3.7% of Organovo shares are held by insiders. Comparatively, 0.0% of Panbela Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryOrganovo and Panbela Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get Panbela Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBLA vs. The Competition Export to ExcelMetricPanbela TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.58M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E Ratio0.0010.5990.0517.18Price / SalesN/A196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book-0.025.094.784.78Net Income-$25.26M$151.83M$120.31M$225.60M7 Day Performance1.10%-2.14%-1.92%-1.23%1 Month Performance-6.94%-4.56%13.65%0.46%1 Year Performance-98.17%8.87%28.34%15.24% Panbela Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBLAPanbela TherapeuticsN/A$0.33-1.5%N/A-98.1%$1.58MN/A0.007Gap DownONVOOrganovoN/A$0.39-3.4%N/A-67.6%$6.01M$110,000.000.0020Analyst ForecastSYRSSyros Pharmaceuticals4.2571 of 5 stars$0.22+4.4%$3.33+1,441.1%-96.5%$5.80M$9.94M-0.07120Gap UpGTBPGT Biopharma3.6544 of 5 stars$2.59-5.8%$11.00+324.7%-78.3%$5.79MN/A0.008Positive NewsGap UpCNSPCNS Pharmaceuticals1.2211 of 5 stars$0.10-2.4%$0.50+398.0%-99.8%$5.77MN/A0.005Gap DownHOTHHoth Therapeutics2.0095 of 5 stars$0.83+1.9%$3.50+324.0%-30.8%$5.70MN/A-0.614Gap UpPPBTPurple Biotech1.6642 of 5 stars$4.06+6.0%$33.00+712.8%N/A$5.40MN/A-0.4720CANFCan-Fite BioPharma1.7922 of 5 stars$1.52-3.8%$14.00+821.1%-30.7%$5.38M$667,000.00-0.888ELABElevai Labs0.3441 of 5 stars$2.07-9.6%N/A-99.3%$5.36M$2.45M-0.0318News CoverageGap DownIMCCIM Cannabis0.0474 of 5 stars$2.35-4.9%N/A+3.4%$5.25M$51.39M-0.72340Gap DownAEZSAeterna ZentarisN/A$2.90flatN/A-68.1%$5.20M$2.37M-0.2020Analyst Forecast Related Companies and Tools Related Companies Organovo Competitors Syros Pharmaceuticals Competitors GT Biopharma Competitors CNS Pharmaceuticals Competitors Hoth Therapeutics Competitors Purple Biotech Competitors Can-Fite BioPharma Competitors Elevai Labs Competitors IM Cannabis Competitors Aeterna Zentaris Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PBLA) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Panbela Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Panbela Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
